QUEBEC CITY, June 6, 2013 /CNW Telbec/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company"), announced today that the
previously disclosed purported class action lawsuit filed against the
Company and certain of its officers (the "Defendants") by Faruqi &
Faruqi LLP in the United States District Court for the Southern
District of New York has been entirely dismissed with prejudice and
without leave to amend. No payment was made by any of the Defendants to
the plaintiff or his counsel in connection with the lawsuit. The
plaintiff has 30 days from the docketing of the final judgment to file
a notice of appeal, if he determines to do so.
"We are extremely pleased that the Court recognized and confirmed the
Defendants' long-held view that the plaintiff's claims were entirely
without merit and granted in full and with prejudice our motion to
dismiss, producing the outcome that we had expected all along",
commented David Dodd, President and Chief Executive Officer of Aeterna
About Aeterna Zentaris Inc.
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information, visit www.aezsinc.com.
SOURCE: Aeterna Zentaris Inc.
For further information:
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406